• PolyPid posted a Q2 net loss of $7.8 million, narrowing from a $10 million loss a year earlier; loss per share improved to $(0.35).
• R&D spending edged down to $6.1 million, while G&A expenses fell to $1.3 million on lower non-cash PSU vesting charges.
• Cash and cash equivalents totaled $6.6 million at June 30, down from $12.9 million at Dec. 31, excluding $30 million from Azurity.
• FDA accepted the D-PLEX100 NDA with Priority Review; PDUFA goal date set for Nov. 28, 2026, about one quarter earlier.
• Azurity deal triggered $30 million in upfront and near-term milestones; agreement includes up to about $320 million total milestones, royalties up to mid-20%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120730PRIMZONEFULLFEED9806726) on August 12, 2026, and is solely responsible for the information contained therein.